$GCTK
GlucoTrack Inc

2024 Q2 Form 10-Q Financial Statement

#000149315224019999 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $902.0K $803.0K $675.0K
YoY Change 63.41% 25.08% -1.17%
% of Gross Profit
Research & Development $3.589M $2.148M $1.742M
YoY Change 472.41% 234.58% 188.41%
% of Gross Profit
Depreciation & Amortization $8.000K $4.000K -$8.000K
YoY Change 166.67% 0.0% -300.0%
% of Gross Profit
Operating Expenses $4.491M $2.951M $2.417M
YoY Change 280.92% 129.83% 87.8%
Operating Profit -$4.491M -$2.951M
YoY Change 280.92% 129.83%
Interest Expense $2.000K $24.00K $5.000K
YoY Change -33.33% -1300.0% -61.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.489M -$2.927M -$2.412M
YoY Change 281.72% 127.6% 87.41%
Income Tax
% Of Pretax Income
Net Earnings -$4.489M -$2.927M -$2.412M
YoY Change 281.72% 127.6% 87.41%
Net Earnings / Revenue
Basic Earnings Per Share $0.82 -$0.12
Diluted Earnings Per Share $0.82 -$0.12 -$0.11
COMMON SHARES
Basic Shares Outstanding 27.39M shares 26.76M shares 20.89M shares
Diluted Shares Outstanding 5.476M shares 24.96M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.0K $1.497M $4.492M
YoY Change -98.19% 49.25% 94.29%
Cash & Equivalents $159.0K $1.497M $4.492M
Short-Term Investments
Other Short-Term Assets $283.0K $440.0K $376.0K
YoY Change 65.5% 116.75% 461.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $442.0K $1.937M $4.868M
YoY Change -95.06% 60.61% 104.62%
LONG-TERM ASSETS
Property, Plant & Equipment $86.00K $82.00K $27.00K
YoY Change 218.52% 134.29% -32.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.000K $10.00K $10.00K
YoY Change -10.0% 0.0% -47.37%
Total Long-Term Assets $166.0K $169.0K $37.00K
YoY Change 348.65% 275.56% -37.29%
TOTAL ASSETS
Total Short-Term Assets $442.0K $1.937M $4.868M
Total Long-Term Assets $166.0K $169.0K $37.00K
Total Assets $608.0K $2.106M $4.905M
YoY Change -93.23% 68.35% 101.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.736M $1.014M $839.0K
YoY Change 228.85% 55.52% 24.85%
Accrued Expenses $25.00K $24.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $12.00K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.660M $1.482M $1.512M
YoY Change 248.57% 41.55% 49.26%
LONG-TERM LIABILITIES
Long-Term Debt $191.0K $195.0K $196.0K
YoY Change 1.06% 1.04% 0.51%
Other Long-Term Liabilities $191.0K $195.0K $196.0K
YoY Change 1.06% 1.04%
Total Long-Term Liabilities $191.0K $195.0K $196.0K
YoY Change 1.06% 1.04% 0.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.660M $1.482M $1.512M
Total Long-Term Liabilities $191.0K $195.0K $196.0K
Total Liabilities $3.897M $1.730M $1.708M
YoY Change 214.53% 39.52% 41.39%
SHAREHOLDERS EQUITY
Retained Earnings -$117.3M -$112.8M -$109.9M
YoY Change 11.45% 9.3% 7.8%
Common Stock $113.9M $113.1M $113.0M
YoY Change 0.86% 9.58% 9.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.289M $376.0K $3.197M
YoY Change
Total Liabilities & Shareholders Equity $608.0K $2.106M $4.905M
YoY Change -93.23% 68.35% 101.19%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$4.489M -$2.927M -$2.412M
YoY Change 281.72% 127.6% 87.41%
Depreciation, Depletion And Amortization $8.000K $4.000K -$8.000K
YoY Change 166.67% 0.0% -300.0%
Cash From Operating Activities -$1.907M -$2.942M -$2.411M
YoY Change 99.9% 124.07% 156.49%
INVESTING ACTIVITIES
Capital Expenditures $12.00K $59.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$12.00K -$59.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 580.0K 0.000
YoY Change -93.36%
NET CHANGE
Cash From Operating Activities -1.907M -$2.942M -2.411M
Cash From Investing Activities -12.00K -$59.00K 0.000
Cash From Financing Activities 580.0K 0.000
Net Change In Cash -1.339M -$2.995M -2.411M
YoY Change -117.22% 127.24% 157.86%
FREE CASH FLOW
Cash From Operating Activities -$1.907M -$2.942M -$2.411M
Capital Expenditures $12.00K $59.00K $0.00
Free Cash Flow -$1.919M -$3.001M -$2.411M
YoY Change 101.15% 128.56% 157.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1512000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
196000 usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26756369 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26756369 shares
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
733000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2927000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2921000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q1 GCTK Stock Issued During Period Value Issuance Of Restricted Shares As Payment For Achievement Of Milestone Pursuant To Purchase Agreement Note4b
StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
usd
CY2024Q1 GCTK Stock Issued During Period Value Exerciseof Prefunded Warrants Into Shares
StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares
usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1497000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4492000 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
440000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
376000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1937000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4868000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
77000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
82000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27000 usd
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10000 usd
CY2024Q1 us-gaap Assets
Assets
2106000 usd
CY2023Q4 us-gaap Assets
Assets
4905000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1014000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
839000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24000 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
444000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
673000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1482000 usd
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
195000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1730000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1708000 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20892193 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20892193 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
27000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
27000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
113029000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112966000 usd
CY2024Q1 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
78000 usd
CY2023Q4 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
48000 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112780000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109853000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
376000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3197000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2106000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4905000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2148000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
642000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
642000 usd
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
70000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
2951000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1284000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2951000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1284000 usd
CY2024Q1 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
24000 usd
CY2023Q1 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
-2000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1286000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1281000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24959768 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24959768 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15503632 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15503632 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1286000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
57000 usd
CY2023Q1 GCTK Stock To Be Issued During Period Value Restricted Stock Award Gross
StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
5000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3197000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3197000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2927000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
22000 usd
CY2024Q1 GCTK Stock To Be Issued During Period Value Restricted Stock Award Gross
StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
78000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
376000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
376000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2927000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1286000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
22000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
57000 usd
CY2024Q1 GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
78000 usd
CY2023Q1 GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
5000 usd
CY2024Q1 GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
-1000 usd
CY2023Q1 GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
2000 usd
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
64000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
137000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
175000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13000 usd
CY2024Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-229000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
55000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2942000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1313000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59000 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2995000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1318000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4502000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2331000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1507000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1013000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
28000 usd
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
79000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112780000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1497000 usd
CY2023 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
8730000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zLEhUdn28oid" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. </b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zTRBX01rGBC1">Use of Estimates in the Preparation of Financial Statements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Management believes that there are no critical accounting estimates in these financial statements.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0903 pure
CY2024Q1 GCTK Additions To Operating Lease Liability
AdditionsToOperatingLeaseLiability
79000 usd
CY2024Q1 GCTK Interst Expense On Lease Liability
InterstExpenseOnLeaseLiability
1000 usd
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
77000 usd
CY2024Q1 GCTK Amortization Of Right For Usage Asset
AmortizationOfRightForUsageAsset
2000 usd
CY2024Q1 GCTK Interst Expense On Lease Liability
InterstExpenseOnLeaseLiability
1000 usd
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3000 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
3000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
88000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
100000 shares
CY2023 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
131000 usd

Files In Submission

Name View Source Status
0001493152-24-019999-index-headers.html Edgar Link pending
0001493152-24-019999-index.html Edgar Link pending
0001493152-24-019999.txt Edgar Link pending
0001493152-24-019999-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gctk-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gctk-20240331_cal.xml Edgar Link unprocessable
gctk-20240331_def.xml Edgar Link unprocessable
gctk-20240331_lab.xml Edgar Link unprocessable
gctk-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending